Disease Etiology and Outcomes After Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma: Post-Hoc Analysis of IMbrave150

Review Gastroenterology & Hepatology

Emerging immunotherapy or HCC: A guide for hepatologists

Friedrich Foerster et al.

Summary: HCC is one of the most common and deadliest cancers globally. Immuno-oncology has shown promising results in the treatment of HCC, with immune checkpoint inhibition becoming the first-line therapy for advanced cases. However, challenges remain in determining the role of immunotherapy in earlier stages of HCC and identifying treatment strategies for non-responsive patients.

HEPATOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Steatohepatitis Impairs T-cell-Directed Immunotherapies Against Liver Tumors in Mice

Bernd Heinrich et al.

Summary: This study found that steatohepatitis reduces infiltration of CD4(+) T cells and effector memory cells in liver tumors, which decreases the efficacy of immunotherapeutic agents like M30 and aOX40 in inhibiting tumor growth. N-acetylcysteine can restore T-cell numbers in tumors and enhance the ability of M30 and aOX40 to slow tumor growth in mice.

GASTROENTEROLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Dominik Pfister et al.

Summary: The study investigated the impact of NASH on immunotherapy response in HCC patients and found that NASH-HCC may be less responsive to immunotherapy. Aberrant T cell activation caused by NASH-related tissue damage led to impaired immune surveillance in HCC patients.

NATURE (2021)

添加到收藏夹

Review Gastroenterology & Hepatology

Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020)

Philipp K. Haber et al.

Summary: A review of 49 high-quality phase III randomized controlled trials in hepatocellular carcinoma conducted between 2002 and 2020 found that 9 had positive results, suggesting that immunotherapies may be more effective in viral etiologies.

GASTROENTEROLOGY (2021)

添加到收藏夹

Editorial Material Medicine, General & Internal

Hepatocellular Carcinoma - Origins and Outcomes

Robin K. Kelley et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Dominik Pfister et al.

Summary: The text discusses the impact of NASH on the development of HCC and the effect of immunotherapy, revealing the accumulation of exhausted and unconventionally activated CD8(+)PD1(+) T cells in NASH-affected livers. In preclinical models of NASH-induced HCC, anti-PD1 treatment led to an increase in HCC, with CD8(+) T cells contributing to this increase.

NATURE (2021)

添加到收藏夹

Article Gastroenterology & Hepatology